Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


07.11.2022

2 Aliment Pharmacol Ther
1 Am J Gastroenterol
4 Clin Gastroenterol Hepatol
3 Eur J Gastroenterol Hepatol
1 Gut
13 Inflamm Bowel Dis
1 J Clin Gastroenterol
10 J Crohns Colitis
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
    Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
    PubMed         Abstract available

  2. COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
    Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
    PubMed         Abstract available


    Am J Gastroenterol

  3. BIRCH RJ, Burr N, Subramanian V, Tiernan JP, et al
    Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.
    Am J Gastroenterol. 2022;117:1858-1870.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  4. GIRI S, Angadi S, Jearth V
    Deep Remission in Crohn's Disease: Optional or Quintessential.
    Clin Gastroenterol Hepatol. 2022;20:2654-2655.
    PubMed        

  5. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study.
    Clin Gastroenterol Hepatol. 2022;20:2588-2597.
    PubMed         Abstract available

  6. HANZEL J, Jairath V, Ma C, Guizzetti L, et al
    Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2598-2606.
    PubMed         Abstract available

  7. CARON B, Abreu MT, Siegel CA, Panaccione R, et al
    IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus.
    Clin Gastroenterol Hepatol. 2022;20:2619-2627.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  8. FOUSEKIS FS, Katsanos KH, Popovic DD
    Translation and validation of questionnaires: necessary processes for inflammatory bowel disease studies reliability.
    Eur J Gastroenterol Hepatol. 2022;34:1201-1202.
    PubMed        

  9. MARTINHO-GRUEBER M, Kapoglou I, Bravo F, Sarraj R, et al
    Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
    Eur J Gastroenterol Hepatol. 2022 Oct 26. pii: 00042737-990000000-00082.
    PubMed         Abstract available

  10. NARULA N, Wong ECL, Moayyedi P, Reinisch W, et al
    Pilot study of an elimination diet in adults with mild to moderate Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:1210-1219.
    PubMed         Abstract available


    Gut

  11. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Nov 2. pii: gutjnl-2022-328883. doi: 10.1136/gutjnl-2022-328883.
    PubMed        


    Inflamm Bowel Dis

  12. INOUE A, Bartlett DJ, Shahraki N, Sheedy SP, et al
    Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography.
    Inflamm Bowel Dis. 2022;28:1677-1686.
    PubMed         Abstract available

  13. LIMKETKAI BN, Hamideh M, Shah R, Sauk JS, et al
    Dietary Patterns and Their Association With Symptoms Activity in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2022;28:1627-1636.
    PubMed         Abstract available

  14. PANES J, Bouma G, Ferrante M, Kucharzik T, et al
    INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.
    Inflamm Bowel Dis. 2022;28:1737-1745.
    PubMed         Abstract available

  15. ATTAUABI M, Wewer MD, Bendtsen F, Seidelin JB, et al
    Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis.
    Inflamm Bowel Dis. 2022;28:1756-1765.
    PubMed         Abstract available

  16. RAMOS L, Hernandez-Porto M, Carrillo-Palau M, Alonso-Abreu I, et al
    Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2022 Nov 2. pii: 6793895. doi: 10.1093.
    PubMed        

  17. SAVELKOUL EHJ, Thomas PWA, Derikx LAAP, den Broeder N, et al
    Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.
    Inflamm Bowel Dis. 2022 Nov 1. pii: 6786024. doi: 10.1093.
    PubMed         Abstract available

  18. BOYD T, Friedman S
    Challenges and Opportunities for Advancing Research and Improving Care for Sexual and Gender Minorities With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2022 Oct 29. pii: 6779855. doi: 10.1093.
    PubMed        

  19. SCHWEDA A, Becker E, Wiendl M, Atreya R, et al
    Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.
    Inflamm Bowel Dis. 2022;28:1746-1755.
    PubMed         Abstract available

  20. CHAPARRO M, Baston-Rey I, Fernandez-Salgado E, Gonzalez Garcia J, et al
    Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Inflamm Bowel Dis. 2022;28:1725-1736.
    PubMed         Abstract available

  21. MAHMUD N, Shah Y, Khan N
    Prevalence of SARS-COV-2 Vaccination and Factors Impacting Likelihood of Vaccination in a Nationwide Veterans Affairs Cohort of IBD Patients.
    Inflamm Bowel Dis. 2022;28:1776-1780.
    PubMed        

  22. XU L, Huang G, Cong Y, Yu Y, et al
    Sex-related Differences in Inflammatory Bowel Diseases: The Potential Role of Sex Hormones.
    Inflamm Bowel Dis. 2022;28:1766-1775.
    PubMed         Abstract available

  23. KREISS L, Thoma OM, Lemire S, Lechner K, et al
    Label-Free Characterization and Quantification of Mucosal Inflammation in Common Murine Colitis Models With Multiphoton Imaging.
    Inflamm Bowel Dis. 2022;28:1637-1646.
    PubMed         Abstract available

  24. DALAL RS, Bains K, Marcus J, McClure EL, et al
    Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series.
    Inflamm Bowel Dis. 2022;28:1787-1789.
    PubMed        


    J Clin Gastroenterol

  25. GUTIERREZ-VALENCIA M, Leache L, Saiz LC, Beloqui JJ, et al
    Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Clin Gastroenterol. 2022 Nov 3. pii: 00004836-990000000-00089.
    PubMed         Abstract available


    J Crohns Colitis

  26. ELLUL P, Schembri J, Baldacchino VA, Molnar T, et al
    Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794125. doi: 10.1093.
    PubMed         Abstract available

  27. DUPONT-LUCAS C, Leroyer A, Ley D, Spyckerelle C, et al
    Increased risk of cancer and mortality in a large French population-based paediatric-onset inflammatory bowel disease retrospective cohort.
    J Crohns Colitis. 2022 Nov 1. pii: 6783208. doi: 10.1093.
    PubMed         Abstract available

  28. BOUCHER D, Barnich N
    Phage Therapy Against Adherent-invasive E. coli: Towards a Promising Treatment of Crohn's Disease Patients?
    J Crohns Colitis. 2022;16:1509-1510.
    PubMed        

  29. DAL BUONO A, Faita F, Peyrin-Biroulet L, Danese S, et al
    Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment.
    J Crohns Colitis. 2022;16:1637-1646.
    PubMed         Abstract available

  30. DE VOOGD F, Bots S, Gecse K, Gilja OH, et al
    Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFalpha Treatment in Crohn's Disease.
    J Crohns Colitis. 2022;16:1598-1608.
    PubMed         Abstract available

  31. DUBINSKY V, Reshef L, Rabinowitz K, Wasserberg N, et al
    Escherichia coli Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations.
    J Crohns Colitis. 2022;16:1584-1597.
    PubMed         Abstract available

  32. MONFORT-FERRE D, Caro A, Menacho M, Marti M, et al
    The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn's Disease.
    J Crohns Colitis. 2022;16:1571-1583.
    PubMed         Abstract available

  33. HU S, Mok J, Gowans M, Ong DEH, et al
    Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations.
    J Crohns Colitis. 2022;16:1628-1636.
    PubMed         Abstract available

  34. KUMAR S, Parry T, Mallett S, Bhatnagar G, et al
    Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn's Disease: Experience from the METRIC Trial.
    J Crohns Colitis. 2022;16:1531-1539.
    PubMed         Abstract available

  35. BATTAT R, Scherl EJ, Lukin D, Charilaou P, et al
    Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794155. doi: 10.1093.
    PubMed         Abstract available


    PLoS One

  36. THOMAS S, Mercogliano G, Prendergast GC
    Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment.
    PLoS One. 2022;17:e0276910.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: